
ACHV Stock Forecast & Price Target
ACHV Analyst Ratings
Bulls say
Achieve Life Sciences is a promising investment due to its potential for FDA approval, success in clinical trials for smoking cessation, and a large market for tobacco users. With a well-prepared commercial launch and plans for global expansion, the company has a strong outlook for growth and profitability. Valuation for the company is based on a risk-adjusted, DCF analysis of the opportunity for its new drug cytisinicline, which has shown impressive results in reducing cravings and withdrawal symptoms for both smoking and vaping.
Bears say
Achieve Life Sciences is a pre-revenue company with one product in late-stage clinical trials and lacks diversification in its pipeline. Despite positive results from their Phase 2 and Phase 3 trials for cytisinicline, uptake for this treatment may be slow and competition in the smoking cessation market is strong. In addition, Achieve Life Sciences is solely focused on addressing nicotine dependence, which limits their potential for growth and revenue diversification.
This aggregate rating is based on analysts' research of Achieve Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
ACHV Analyst Forecast & Price Prediction
Start investing in ACHV
Order type
Buy in
Order amount
Est. shares
0 shares